Skip to content

Multidisciplinary Collaborative Microneurodecompression for Refractory Migraine: Technical Application and Efficacy Study

Multidisciplinary Collaborative Microneurodecompression for Refractory Migraine: Technical Application and Efficacy Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121979
Enrollment
Unknown
Registered
2026-04-07
Start date
2026-04-07
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Patients with refractory migraine treated by multidisciplinary collaborative microneurodecompression.:Microscopic Neurodecompression under the Multidisciplinary Team (MDT) Model

Sponsors

Xiamen University Affiliated Zhongshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for refractory migraine defined by the International Headache Society (IHS). 2. Age 18 to 75 years old, either gender. 3. Failure of treatment with >=3 classes of migraine preventive medications. 4. Positive nerve block test (pain relief >= 80%). 5. Voluntary participation in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary headache caused by organic diseases such as intracranial tumor, infection, cerebrovascular malformation or trauma. 2. Severe cardiac, hepatic, renal or coagulation dysfunction, unable to tolerate surgery and anesthesia. 3. Pregnant or lactating women. 4. Mental illness or cognitive impairment that prevents cooperation in the study and follow-up. 5. Participation in other clinical intervention studies within the past 3 months. 6. Other conditions judged by the investigator to be unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with =50% reduction in monthly headache days (MHD) at 12 months postoperatively.;=30% improvement in Headache Impact Test (HIT?6) score.;Success rate of medication overuse headache (MOH) withdrawal (target >80%).;

Secondary

MeasureTime frame
Visual Analogue Scale (VAS) score: complete pain relief rate (VAS =1) and overall effective rate (VAS reduction =50%).;Migraine Disability Assessment Scale (MIDAS) score and analgesic medication consumption.;36?Item Short Form Health Survey (SF?36) score.;Incidence of surgical complications (paresthesia, incision infection, etc.).;Patient satisfaction score (NRS).;

Countries

China

Contacts

Public ContactFeng Wei

Xiamen University Affiliated Zhongshan Hospital

weifeng@xmu.edu.cn+86 592 299 3161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026